Clinical Trial Update: An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 efficacy and safety study of JNJ-26113100 for adult atopic dermatitis was terminated, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• JNJ-26113100

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Atopic Dermatitis | Phase 2 | Status: TERMINATED | Results posted: 2013-07-01